The vast majority of new drugs have been developed in nations without extensive price controls on the industry.

Etienne Barral, who is probably the uncredited source for the numbers in your link, also showed that

...three nations with relatively few price constraints - the US, Switzerland and Britain - produced 102 of the 152 new drugs that became global products between 1975 and 1994. A total of 45 per cent of the new products were from US companies.

Consider the example of France, which forces companies to agree to prices before they can sell new drugs. The Barral study found that country produced only 3 per cent of drugs between 1975-1994. Bigger companies such as Rhône-Poulenc could get around that by merging with groups in freer markets; today Rhône-Poulenc is part of Aventis, which markets and researches heavily in the US.

I doubt that someone who calls the industry "Big Pharm," while writing an article for a paper in a country with basically "No Pharm," is going to tell us how it is.

Thank God we have "Big Pharm" in America to keep the rest of the world healthy.